A number of new immunosuppressive drugs have become available in transplant medicine. We investigated the effects of two different immunosuppressive protocols on bronchoalveolar lavage fluid cellular characteristics in 34 lung transplant recipients who were treated with anti-thymocyte globulin induction therapy, cyclosporine, azathioprine (AZA), and prednisolone (regimen I), compared with 17 recipients receiving basiliximab induction, tacrolimus, AZA, and prednisolone (regimen II). We performed bronchoalveolar lavages between 15 and 40 d post-transplantation, in stable clinical condition and no acute rejection, cytomegalovirus, and/or respiratory tract infection. The regimen II treatment was associated with a significantly lower percentage ...
Early diagnosis and treatment of acute cellular rejection (ACR) may improve long-term outcome for lu...
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. The aim o...
Lung transplant remains a key therapeutic option for patients with end stage lun...
A number of new immunosuppressive drugs have become available in transplant medicine. We investigate...
Background: T lymphocytes are crucial in lung allorejection. The contribution of lymphocyte subtypes...
Allograft rejection remains a major cause of morbidity and mortality following lung transplantation ...
BackgroundLung transplant tolerance depends on effective control of T-cell proliferation and activat...
The definitive version is available at www.blackwell-synergy.comCurrent immunosuppression protocols ...
P>Immunosuppression therapy following lung transplant fails to prevent chronic rejection/bronchiolit...
ObjectiveEffects of daclizumab and antithymocyte globulin induction on acute rejection, bronchioliti...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
BACKGROUND: The detection of graft rejection by bronchoalveolar lavage remains controversial.METHODS...
Background. Allograft rejection remains a major cause of morbidity and mortality after lung transpla...
Lymphocytic airway inflammation is a major risk factor for chronic lung allograft dysfunction, for w...
Background: Recent publications have demonstrated potentially pathologic changes in bronchoalveolar ...
Early diagnosis and treatment of acute cellular rejection (ACR) may improve long-term outcome for lu...
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. The aim o...
Lung transplant remains a key therapeutic option for patients with end stage lun...
A number of new immunosuppressive drugs have become available in transplant medicine. We investigate...
Background: T lymphocytes are crucial in lung allorejection. The contribution of lymphocyte subtypes...
Allograft rejection remains a major cause of morbidity and mortality following lung transplantation ...
BackgroundLung transplant tolerance depends on effective control of T-cell proliferation and activat...
The definitive version is available at www.blackwell-synergy.comCurrent immunosuppression protocols ...
P>Immunosuppression therapy following lung transplant fails to prevent chronic rejection/bronchiolit...
ObjectiveEffects of daclizumab and antithymocyte globulin induction on acute rejection, bronchioliti...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
BACKGROUND: The detection of graft rejection by bronchoalveolar lavage remains controversial.METHODS...
Background. Allograft rejection remains a major cause of morbidity and mortality after lung transpla...
Lymphocytic airway inflammation is a major risk factor for chronic lung allograft dysfunction, for w...
Background: Recent publications have demonstrated potentially pathologic changes in bronchoalveolar ...
Early diagnosis and treatment of acute cellular rejection (ACR) may improve long-term outcome for lu...
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. The aim o...
Lung transplant remains a key therapeutic option for patients with end stage lun...